Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02446223 · ClinicalTrials.gov registry record · Phase 4
Evaluate the Efficacy and Safety of Large-Scale Field-Directed Topical Therapy of Actinic Keratosis of the Chest w/Ingenol Mebutate 0.015%
A Phase 4 study, sponsored by Goldman, Butterwick, Fitzpatrick and Groff.
- Completed
- Registry status
- Phase 4
- Development phase
- 21
- Enrollment target
NCT02446223 is a Phase 4 study that has completed, run by Goldman, Butterwick, Fitzpatrick and Groff. The registered enrollment target is 21 participants.
The verdict
NCT02446223, a Phase 4 study, has completed, sponsored by Goldman, Butterwick, Fitzpatrick and Groff.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 21 participants
- Enrollment target
Study Summary
Evaluate the Efficacy and Safety of Large-Scale Field-Directed Topical Therapy of Actinic Keratosis of the Chest w/Ingenol Mebutate 0.015%
Interventions
- DRUG Inggenol Mebutate 0.015%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2015-01 |
| Est. Completion | 2016-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02446223
The ClinicalTrials.gov registry entry for NCT02446223 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Goldman, Butterwick, Fitzpatrick and Groff, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Inggenol Mebutate 0.015% is the first listed.
NCT02446223 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02446223 about?
NCT02446223 is a clinical study titled "Evaluate the Efficacy and Safety of Large-Scale Field-Directed Topical Therapy of Actinic Keratosis of the Chest w/Ingenol Mebutate 0.015%". Evaluate the Efficacy and Safety of Large-Scale Field-Directed Topical Therapy of Actinic Keratosis of the Chest w/Ingenol Mebutate 0.015%
What is the current status of trial NCT02446223?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2015-01. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02446223?
The interventions under investigation include: Inggenol Mebutate 0.015% (DRUG).
Who is sponsoring clinical trial NCT02446223?
This trial is sponsored by Goldman, Butterwick, Fitzpatrick and Groff, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.